NewMed and Aphrodite: The Egypt MOU makes the project more real, but it still does not close the development gap

Know The Company

NewMed is still, first of all, Leviathan. That is the asset that generates most of the cash, the project that already received a final investment decision in January 2026 for its next expansion stage, and the engine through which the market usually reads the partnership. But around Aphrodite, something did happen in April 2026 that changes the probability map: after years of plans, PSC amendments, and export-route discussions, the partners initialed an MOU to sell gas from Aphrodite into Egypt, and in parallel signed a Host Government Agreement related to the transmission project.

That is real progress. It is not cosmetic, and it is not just another presentation slide. The April 9, 2026 filing describes a commercial basis for a binding agreement with EGAS for the gas volumes recoverable from the field, alongside an HGA that is meant to govern the regulatory framework for building the transmission infrastructure in Egyptian waters. In simple terms, Aphrodite moved one step forward in the chain between a discovered offshore resource and a real end market.

But that is still very far from calling Aphrodite a closed project. Exactly where the headline sounds strongest, the annual report and the immediate filing also remind readers what remains open: the binding agreement itself has not been signed; additional agreements are still needed for the pipeline, operations, connections, and fiscal regime; a final investment decision is still required; and as of the approval date of the annual report, the Israel-Cyprus Aphrodite-Yishai arrangement had still not been finalized.

This chart explains why the analysis cannot stop at the headline. The approved FEED budget, meaning the front-end engineering and design stage, is a manageable check for a partnership of NewMed's current scale. An estimated development cost of about $4.1 billion is a very different story. NewMed's gross share at a 30% working interest is roughly $1.23 billion. That is before timing, financing structure, and whatever the completed FEED may still change.

Events And Triggers

To read Aphrodite correctly, the sequence matters. In the annual report, NewMed describes four key milestones:

1. On February 14, 2025, the Cypriot government approved an updated development plan for the field.
2. On December 22, 2025, the partners decided to begin FEED for the production systems and transmission infrastructure, with a budget of about $105.7 million on a 100% basis, of which NewMed's share is about $31.7 million.
3. On March 9, 2026, the partnership published an updated resource report effective February 28, 2026, after the development-plan approval and entry into FEED.
4. On April 9, 2026, the partners initialed the EGAS MOU and, in parallel, the HGA tied to the transmission project.

What does the approved development plan actually say? According to the annual report, the updated plan is based on a floating production facility, with maximum production capacity of about 800 MMCF per day through 4 production wells, with gas then sent through a subsea pipeline into the Egyptian transmission system. This is important because it means the export logic is not detached from an approved engineering plan. There is already an approved development concept, a FEED budget, and a stated export route.

The April filing adds a commercial and governmental layer. On one side, the MOU is supposed to serve as the basis for a binding gas sales agreement with EGAS. On the other, the HGA is supposed to enable the transmission project through an Egyptian special-purpose vehicle called AMC, to be owned by the Aphrodite partners and an Egyptian government-designated entity.

But even the positive triggers come with a clock. The MOU remains in force until a binding agreement is signed or for 12 months, whichever comes first. The HGA sets a 12-month period to sign the additional agreements needed for the project, followed by another 12-month window to reach FID. If those steps are not completed on time, the agreement can be opened to cancellation.

In other words, the real change is not that all the key pieces of Aphrodite's development are now closed, but that what used to be an open-ended theoretical path has turned into a contractual timetable. That is good because it creates a route. But it also makes execution much easier to measure.

The table below puts the milestones in order:

Economics, Profitability, And Competitive Position

The key question in Aphrodite is not whether there is gas, but how much of that gas already sits on a concrete commercialization path. Here, the April 9 filing and the March 9 resource report together create a more nuanced picture than the headline alone.

On the positive side, the MOU clearly marks progress. It refers to the sale of the recoverable gas volumes from the field, with pricing linked to Brent and including both a floor and a ceiling, plus a take-or-pay mechanism for a minimum annual quantity. During the second period of the agreement, which is supposed to run for at least 6 years, the contractual daily quantity is set at 700 MMSCF per day. That is no longer the language of market sounding. It is the language of commercial structure.

On the other hand, the updated resource report reminds readers that not all of the resource sits at the same maturity level. The new report splits contingent resources between Development Pending and Development Unclarified. On a best-estimate basis, about 2,881 BCF is classified as Development Pending, while about 784 BCF is classified as Development Unclarified. That differs from the previous report, in which all contingent resources were classified as Development Pending.

This is one of the most important charts in the article. It shows that the MOU does not eliminate the maturity problem. A meaningful part of the contingent resource is still outside the clearly defined development path. So anyone reading the phrase full gas volumes as if all contingent resources have already moved into one commercial bucket is moving ahead of the evidence.

The resource report itself says the higher estimates mainly reflect two factors: an updated geological model based on core-lab work from the A-3 well, and the development-plan approval plus entry into FEED, which allowed a more precise characterization of the planned production systems, number of wells, and expected daily production.

Again, the message is double-sided. The move into FEED and the approved development plan improved the read on the contingent resource. But prospective resources did not change, which means the upgrade is still mainly about the discovered resource layer, not a fresh optionality story.

That leads to the business conclusion. The MOU improves the demand side, and the HGA improves the infrastructure and host-government side. But neither one erases the fact that part of the resource is still not targeted under the current plan, and that the FEED process can still change the read on cost, timing, and possibly even commercialization details.

That is also where competition matters here. The relevant competition is not really another field. It is competition against cost of capital, alternative export routes, and NewMed's own capital priorities. Leviathan already has FID and an expansion path to 21 BCM. Aphrodite is still competing first for the right to become a funded development project.

Cash Flow, Debt, And Capital Structure

This is where the gap between a positive headline and accessible value becomes much clearer. For NewMed, Aphrodite FEED is not, by itself, a heavy financing test. According to the investor presentation, FEED stands at about $105.7 million on a 100% basis, and NewMed's share is about $31.7 million. The full Aphrodite 2026 budget is about $111.5 million on a 100% basis, NewMed's share about $33.5 million.

At the partnership level, the 2025 presentation shows cash and cash equivalents of $107.7 million, short-term deposits of $49.8 million, and net financial debt of $1.234 billion as of December 31, 2025. The same presentation also says the partnership had $600 million of undrawn bank facilities available at the financial-statement publication date.

So in the immediate term, Aphrodite does not look like a balance-sheet breaker. But that is only half the picture. The other half is that the operator's estimated cost of the updated development plan, before FEED is completed, stands at about $4.1 billion on a 100% basis. And this comes at a time when NewMed is already in another investment cycle, because on January 15, 2026, the Leviathan partners took FID on the first stage of the expansion project, with a total budget of about $2.36 billion on a 100% basis and first gas expected in the second half of 2029.

This is the point the market may miss at first glance. Aphrodite improved commercially before it improved financially. The partnership can clearly carry FEED. But if the project reaches FID, NewMed will have to deal not just with Aphrodite economics but with how two large offshore development programs coexist in one capital structure.

And this is where precision matters. The filings do not yet provide a finished picture of the project's financing structure, the eventual leverage mix, or how much of the burden will sit at the partner layer versus project finance. So it is too early to declare the true burden on unitholders. What can already be said is that the MOU did not remove the funding question. It only made it more relevant.

Outlook

Before the detail, here are the 4 non-obvious findings that matter most:

1. Commercialization moved faster than financing. Aphrodite got a route-to-market frame before it got a closed financing frame.
2. The real clock is now a 12-month clock, not a multi-year abstract path. The MOU and HGA create measurable deadlines.
3. Not all of the resource sits in the same maturity bucket. Part of 2C still remains Development Unclarified.
4. 2031 is a possible first-gas target, not a starting assumption. Both the annual report and the April filing still tie it to FEED, agreements, approvals, and FID.

What could strengthen the thesis in the near to medium term? First, the completion of government authorizations and full signatures, which NewMed said in April 2026 were expected in the coming weeks. Second, relatively fast conversion of the MOU into a binding agreement with EGAS and into the additional agreements required by the HGA. Third, separate but complementary progress in the Israel-Cyprus Aphrodite-Yishai arrangement.

What could weigh on the thesis? Any sign that the 12-month windows are starting to erode without real closure. The FRA is also a key pressure point, because it still needs both signature and Egyptian parliamentary approval. In addition, if FEED leads to a further jump in the cost estimate, the market may need to re-read both the economics of Aphrodite and NewMed's ability to carry it alongside Leviathan.

There is also a gap between what the headline says and what the market may ultimately price. The headline says all Aphrodite gas is heading to Egypt. But the filings still route the project through a fiscal regime, a transmission SPV, cross-border approvals, and an FID that has not yet been taken. So what may surprise positively is speed of closure, not the existence of the MOU itself.

Risks

Aphrodite remains a project with several open layers of risk even after April 2026:

1. Inter-governmental regulatory risk. As of the annual report approval date, Israel and Cyprus still had not signed an intergovernmental agreement on Aphrodite-Yishai.
2. Contract risk. Both the MOU and the HGA create frameworks, but both still rely on additional agreements and on defined timelines being met.
3. Egyptian fiscal risk. The FRA is still under discussion and still requires both signature and parliamentary approval.
4. Engineering and financing risk. The $4.1 billion cost estimate comes before FEED is complete, so it is not a final number.
5. Regional and geopolitical risk. Both the annual report and the immediate filing highlight sensitivity to geopolitical, security, and operating conditions in the region.

There is also a more subtle risk, but an important one: Aphrodite may start sounding more advanced than it really is. In the filings that point appears almost everywhere. There is improvement, but it has not yet reached the investment-commitment layer.

Conclusions

The Egypt MOU is a real step forward for Aphrodite, but not the same step that the market may assume at first glance. It does not make Aphrodite a near-term cash engine, and it does not replace FID. What it does do is narrow the commercialization gap. Suddenly there is a defined potential buyer, a host-government framework for transmission, a contractual timetable, and better alignment between the development concept and the marketing path.

That matters because until now Aphrodite was mainly a field with a plan. Now it is also a field with an initial commercial route. But in the same breath, the filings show that the real test has simply moved to a different point: no longer whether there is a theoretical path to development, but whether NewMed and its partners can close the full chain of contracts, approvals, and financing on a relatively fast timetable.

So the right conclusion at this stage is two-sided. Aphrodite is more tangible, but not simpler. Anyone looking only at the headline will see a field that is almost sold. Anyone reading the filings will see a project that is advancing well, but still has to get through a binding agreement, FRA, full HGA implementation, FID, intergovernmental settlement, and a financing plan that fits with the fact that NewMed is already in a large Leviathan expansion cycle.

If the partnership closes the additional agreements on time, keeps FEED from materially changing the cost frame, and shows that the Israel-Cyprus arrangement is moving, Aphrodite could move in 2026 and 2027 from a regional option into a genuine development project. If not, April 2026 may be remembered not as a full turning point, but as another meaningful stage on the long road to FID.